Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma

Abstract Background Osteosarcoma (OS) is the most common primary bone tumor in children and adolescent. Surgery and multidrug chemotherapy are the standard of treatment achieving 60–70% of event-free survival for localized disease at diagnosis. However, for metastatic disease, the prognosis is disma...

Full description

Bibliographic Details
Main Authors: Caterina Cascini, Chiara Ratti, Laura Botti, Beatrice Parma, Valeria Cancila, Adriana Salvaggio, Cristina Meazza, Claudio Tripodo, Mario P. Colombo, Claudia Chiodoni
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Osteosarcoma
Immunomodulation
Lymphocyte activation
Macrophages
TLR9
Mouse models
Online Access:https://doi.org/10.1186/s13046-023-02731-z

Internet

https://doi.org/10.1186/s13046-023-02731-z

Similar Items